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Abstract
Background. End stage renal disease increases the risk of
reactivating latent tuberculosis (LTBI). Interferon-γ release
assays (IGRA) are an alternative to the tuberculin skin test
(TST) for detecting LTBI.
Methods. Sixty-two hemodialysis patients (46 male, 16
female, aged 65 ± 15 years) from 3 hemodialysis facili-
ties in the Geneva area were submitted to a TST, 2 IGRA
(T-SPOT.TB and QuantiFERON Gold in tube: QFT), a chest
radiography, and a questionnaire to record social status,
country of birth, history of prior TST, tuberculosis (TB),
BCG (Bacillus of Calmette-Gue´rin vaccine), and any cause
of immuno-suppression. LTBI was defined as prior “at risk”
contact with a case of contagious TB and/or a chest X-ray
suggestive of prior TB infection.
Results. Positivity rate was 19% for TST, 21% for QFT and
29% for T-SPOT-TB; 8% of QFT and 11% of T-SPOT-TB
were indeterminate. Agreement between IGRA was fair
(κ = 0.60). After adjusting for age and BCG, OR (Odds
Ratio) of having a positive QFT was 4.6-fold (p = 0.029)
higher in patients with LTBI vs. those without LTBI. In con-
trast, no association was found between LTBI and having a
positive T-SPOT.TB or a positive TST. As expected, there
was a strong association between prior BCG vaccination
and having a positive TST (OR 5.3, p = 0.017). QFT was
the only test with a significant OR of having LTBI (adjusted
OR: 4.4; 95%CI: 1.1 − 17.6; p= 0.034). Among 5 patients
with definite prior TB, TST and T-SPOT.TB were positive
in 1 and QFT, in 2.
Conclusions. In this population, QFT was superior to TST
for detecting LTBI, but both IGRAs and TST have impor-
tant limitations, and are unreliable for screening for LTBI.
Keywords: chronic renal failure; haemodialysis; interferon-gamma
release assays; latent tuberculosis infection
Introduction
Tuberculosis (TB) remains a major worldwide public health
problem with over 9 million newly diagnosed cases in 2006
[1]. Due to their defective immune system, dialysis patients,
once infected by bacilli of the Mycobacterium tuberculo-
sis complex, are particularly prone to develop active tu-
berculosis. Nosocomial transmission of TB has also been
reported in patients under long-term dialysis [2]. Studies
report an 8-fold increase in tuberculosis incidence in pa-
tients on dialysis compared to the general population [3].
Detection of latent tuberculosis infection (LTBI) in this
population is therefore an important issue, to prevent pro-
gression to active tuberculosis and secondary contamina-
tion to other patients and health-care workers. For decades,
tuberculin skin testing (TST) has been used as the sole
screening test for LTBI, but with disappointing results in
dialysis patients in whom anergy rate may reach 44% [4–
6]. Indeed, uraemia partly inhibits cellular immunity, which
leads to false negative skin tests [7]. Moreover, specificity
of TST is low, with false positive results due to either BCG
(Bacillus of Calmette-Gue´rin) vaccination or exposure to
environmental mycobacteria. Over the past 5 years, two
in vitro T-cell-based assays have been commercialized
(QuantiFERON Gold R© in tube, Cellestis Ltd, Carnegie,
Australia, and T-SPOT.TB R©, Oxford Immunotec, UK):
both measure the production of Interferon-γ (IFN-γ) by
peripheral blood mononuclear cells after overnight incuba-
tion with antigens of the M. tuberculosis complex, which
are present neither on the BCGMycobacterium Bovis strain
nor on most environmental mycobacteria [8]. Both tests,
commonly referred to as Interferon-gamma Release As-
say (IGRA) (IFN-γ Release Assays), are therefore more
specific than the conventional TST, i.e. do not yield false
positive results after BCG vaccination or infection with
environmental mycobacteria [9,10]. Although perfor-
mances of IGRAs are better than that of TST for the de-
tection of LTBI in immuno-suppressed individuals [11],
data concerning sensitivity and rate of indeterminate tests
of IGRAs in haemodialyzed patients are scarce. To our
knowledge, only two studies [12,13] have analysed the rel-
ative contribution of IGRAs and TST in patients on dialysis.
Both showed a higher rate of positivity for the IGRA tested
versus the TST; both studies also reported a higher rate
of indeterminate results than that documented in immuno-
competent subjects [12,13]. To date however, no study has
compared diagnostic performance for LTBI of both IGRA
and the TST in this population.
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The aim of the present study was therefore to determine
the performances of both IGRAs versus the TST for detect-
ing LTBI (based on patients’ clinical, epidemiological and
radiological data) in a group of hemodialysis patients, and
to investigate the agreement between these tests in this pop-
ulation compared to TST and our expert physician panel.
Patients and methods
This study was performed in three haemodialysis facilities, all located
in the Geneva area (450 000 inhabitants; TB incidence of 20/105/year).
The study protocol was approved by the Geneva University Hospital Ethics
Committee, and is in agreement with the Helsinki declaration of 1975 (and
as revised in 1983). The study was registered at www.clinicaltrials.gov
(N◦: NCT00695734). All patients included provided informed written
consent. All patients under haemodialysis for end-stage renal disease for at
least 3 months were eligible. Exclusion criterion was prior severe reaction
to tuberculin. With the help of a standardized questionnaire and their
medical records, a research nurse recorded the following demographical
and clinical data: age, social status, country of birth, history of prior TST
testing, TB infection and BCG vaccination, presence of scars suggesting
BCG, history of HIV infection or other cause of immuno-suppression. A
chest radiography was performed in all patients included.
A tuberculin skin test (TST) was performed, according to the Mantoux
technique, using two units of purified protein derivative (PPD) RT 23
(Statens Serum Institute, Copenhagen, Denmark), bioequivalent to five
units of the US PPD standard and read after 72 h by two experienced
nurses (readings were averaged). Positivity was defined as an induration
diameter >5 mm.
Blood sampling for determination of M. tuberculosis specific IFN-γ
secreting T-cells (T-SPOT.TB R© and QuantiFERON Gold In tube R©) and
TST were performed simultaneously. Peripheral venous blood samples (8
ml) were processed by our laboratory within 3 h.
T-SPOT.TB R© was processed as previously described [14] and scored
according to the supplier’s instructions. Spot-forming units (SFUs) were
counted with an automated ELISPOT reader (AID system, Strasberg,
Germany). Tests were considered as indeterminate: (1) if SFUs in the
positive control were <20, or (2) if SFUs in the negative well exceeded
10 and both antigen wells had less than twice the number of SFUs of
the negative well. Results were scored as positive if SFU count in either
antigen well was >6 spots above SFUs of negative control, and negative
if [SFU count in highest of early secretory antigen target 6 (ESAT-6) or
culture filtrate protein-10 (CFP-10) wells ] – [SFUs of negative control]
was ≤6 spots.
QuantiFERON Gold In tube R© (QFT): the in-tube assay was performed
according to the manufacturer’s instructions. One millilitre of whole blood
was drawn in each of three separate test tubes: one containing no antigen
(nil control), one with mitogen (phytohaemagglutinin, positive control)
and one with TB antigens (ESAT-6, CFP-10 and TB7.7). The three tubes
were incubated for 18–20 h at 37◦C. Following incubation, the tubes were
centrifuged and plasma removed from each tube and frozen at −20◦C. IFN-
γ measurement by ELISA was subsequently performed in batch testing.
Results were expressed in IU/ml, as determined from a standard curve run
on each plate. According to the supplier’s instruction, a value ≥0.35 IU/ml
for [(IFN-γ in the TB antigen tube) – (IFN-γ in the negative control tube)]
was considered a positive result. If the IFN-γ level was <0.35 IU/ml in the
TB antigen tube and mitogen control was positive (≥0.5 IU/ml), the test
was recorded as negative. If the level in both the TB antigen and mitogen
tubes was less than the threshold of positivity, or the level in the nil tube
was >8.0 IU/ml, then the test was recorded as indeterminate.
Blood samples remained anonymous as they were not used for clinical
decision making.
Statistical analysis
Univariate and parsimonious multivariate logistic regression were used to
identify which factors were associated with the probability of a positive
test. Main predictor of interest was ‘latent tuberculosis infection’ (LTBI)
defined by chest radiography suggestive of prior infection (calcified gran-
uloma or adenopathy, suggestive fibrotic scars) and/or established ‘at risk’
contact with a patient with contagious TB. Covariates (age, BCG status)
were included a priori into the models. Analyses were run separately for
T-SPOT.TB, QFT and TST. Hosmer and Lemeshow goodness-of-fit test
was applied to evaluate model fit: model fit is considered adequate if P >
0.05.
Agreement between tests was quantified using Kappa statistics [15].
Kappa values range from κ = 1 (full agreement) to κ = − 1(full dis-
agreement). The null value (κ = 0) corresponds to an agreement equalling
chance alone. Kappa statistics were then interpreted according to Landis
and Koch: (κ > 0.75: excellent agreement, κ = 0.40 to 0.75: fair to good
agreement, κ < 0.40: poor agreement).
All statistical analyses were performed with STATATM version 10
(Stata corporation, College Station Texas, USA).
Results
Among 95 patients followed by the three haemodialysis fa-
cilities, 62 patients (46 male, 16 female) fulfilled inclusion
criteria and accepted to be included in the present study.
Characteristics of the patients are summarized in Table 1.
Three patients were under low doses of prednisolone
(2.5–5mg/day). Two patients had HIV infection, with re-
spectively 232 and 495 CD4 lymphocytes/mm3. Twenty-
three percent had prior BCG vaccination, and 13 (21%)
had probable LTBI (as previously defined).
Of 10 patients originating from high incidence countries,
4 had positive IGRAs (3 with the QFT and 3 with the
T-SPOT.TB), and only 1 had a TST ≥ 5 mm.
Indeterminate tests occurred in seven (11%) subjects
with T-SPOT.TB versus five (8%) with QFT. Among pa-
tients with indeterminate results, two were indeterminate
with both IGRAs, one received 2.5 mg of prednisolone/day,
four had a low lymphocyte count, including one patient with
HIV infection and 232 CD4 lymphocytes/mm3.
TST induration was >10 mm in 9 subjects and >5 mm
in 12 subjects. Subjects with a positive (>5 mm) TST had
a significantly higher rate of BCG vaccination (P = 0.01)
than those with a negative TST (Table 1).
Rate of LTBI (as defined in the ‘Statistical analysis sec-
tion’) was higher in patients with positive QFT (46.2%)
compared to those with negative QFT (16.3%) (P = 0.02).
Agreement between TST and IGRAs was poor (κ = 0.16
for QFT; P = 0.116, κ = 0.32 for T-SPOT.TB; P = 0.007),
whereas agreement between IGRAs was fair (κ = 0.60;
P < 0.001).
Table 2 shows the association between relevant clinical
items and T-SPOT.TB, QFT or TST results. In univariate
analysis, the OR of having a positive QFT was 4.5-fold
higher (P= 0.029) in patients with LTBI compared to those
without LTBI. After adjusting for age and BCG status, the
association between LTBI and QFT remained significant
(OR 4.6, P = 0.029). In contrast, no association was found
between LTBI and having either a positive T-SPOT.TB or
a positive TST. As expected, there was a strong association
between BCG status and having a positive TST (OR 5.3,
P= 0.017). Accuracies of the models were fair for QFT and
TST with areas under the curve of 0.69 [95% CI: 0.56–0.81]
and 0.71 [95% CI: 0.58–0.81], respectively.
Among five patients with definite prior TB, TST and
T-SPOT.TB were positive in one and QFT, in two.
Table 3 displays the OR of having latent TB using the
three different tests. All tests showed a positive association
with latent TB, but QFT was the only one with a significant
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Table 1. Patient characteristics
All (n = 62) T-SPOT.TB (n = 62) QFT GOLD (n = 62) TST > 5 mm (n = 62)
Positive Negative Positive Negative Positive Negative
Test, positive/negative (n) 18 37 13 44 12 50
Positivity rate (%) 29 21 19
Indeterminate (%) 7(11) 5(8) 0
Age, mean (SD) 65 (15) 66 (13) 62 (17) 66 (19) 64 (15) 62 (15) 65 (16)
TB incidence in country of origin
Low (<50×105 year−1); n, (%) 52 (84) 15 (83) 30 (81) 10 (77) 37 (84) 11 (92) 41 (82)
High (≥50 × 105 year−1); n, (%) 10 (16) 3 (17) 7 (19) 3 (23) 7 (16) 1 (8) 9 (18)
BCG performed; n (%) 14 (23) 4 (22) 8 (22) 2 (15) 11 (25) 6 (50) 8 (16)†
Contact with TB patients, n (%) 8 (13) 3 (17) 5 (14) 3 (23) 5 (11) 1 (8) 7 (14)
Chest X-rays suggestive of tuberculosis, n (%) 8 (13) 1 (6) 5 (14) 3 (23) 5 (11) 2 (17) 6 (12)
Latent tuberculosisb, n (%) 13 (21) 4 (22)a 7 (19)a 6 (46) 7 (16)‡ 3 (25) 10 (20)
QFT Gold: QuantiFERON Gold in tube.
a Total number of T-SPOT.TB in patients with latent TB is 11 versus 13 because of two indeterminate results.
b Latent tuberculosis defined as chest X-ray suggestive of prior TB and/or prior ‘at risk’ contact with a case of contagious TB. Percentages refer to the
total number of subjects with either positive or negative IGRA or TST.
†P = 0.011 for X2 comparing positive and negative TST.
‡P = 0.022 for X2 comparing positive and negative QuantiFERON Gold. For all other positive and negative tests, P values were >0.05.
Table 2. Logistic regression models and odds ratios for positive tests
Univariate OR Multivariate ORa,b
(95% CI) (95% CI)
T-SPOT.TB
Age, years 1.02 (0.98–1.06) 1.02 (0.98–1.06)
High incidence of TB in
country of origin
0.86 (0.19–3.81) –
Prior BCG 1.04 (0.26–4.03) 1.11 (0.28–4.40)
Latent tuberculosisc 1.22 (0.3–4.88) 1.18 (0.29–4.81)
QuantiFERON Gold
Age, years 1.01 (0.97–1.05) 1.00 (0.96–1.05)
High incidence of TB in
country of origin
1.58 (0.35–7.27) –
Prior BCG 0.55 (0.10–2.85) 0.51 (0.09–2.89)
Latent tuberculosisc 4.53 (1.17–17.6) 4.59 (1.16–18.4)
TST >5 mm
Age, years 0.98 (0.95–1.02) 0.98 (0.94–1.02)
High incidence of TB in
country of origin
0.41 (0.05–3.06) –
Prior BCG 5.25 (1.34–20.5) 5.30 (1.34–20.9)
Latent tuberculosisc 1.33 (0.30–5.85) 1.47 (0.31–7.10)
BCG: bacillus of Calmette-Gue´rin.
aAdjusted for age and BCG status.
bHosmer & Lemeshow goodness-of-fit test statistic: all P≥ 0.2 (P> 0.05
indicates adequate model fit).
cLatent tuberculosis defined as chest X-ray suggestive of prior TB and/or
prior ‘at risk’ contact with a case of contagious TB.
Table 3. Logistic regression models for odds ratio of latent tuberculosis
Unadjusted OR Adjusted ORa Adjusted ORb
(95% CI) (95% CI) (95% CI)
T-SPOT.TB 1.2 (0.3–4.9) 1.2 (0.3–4.8) 1.2 (0.3–4.8)
QuantiFERON 4.5 (1.2–17.6) 4.6 (1.2–18.1) 4.4 (1.1–17.6)
Gold
TST > 5 mm 1.3 (0.3–5.9) 1.4 (0.3–7.0) 1.7 (0.3–8.5)
Latent tuberculosis defined as chest X-ray suggestive of prior TB and/or
prior ‘at risk’ contact with a case of contagious TB.
aAdjusted for age and BCG status.
bAdjusted for age, BCG status and TB incidence in country of origin.
association (adjusted OR: 4.4; 95% CI: 1.1–17.6; P =
0.034).
Discussion
This study is to our knowledge the first to compare simul-
taneously the performance of both commercially available
IGRAs with TST for the detection of latent tuberculosis
infection (LTBI) in end-stage renal failure patients under
haemodialysis. Our results show that association between
probable LTBI (defined as: chest radiography suggestive
of prior infection and/or established ‘at risk’ contact with
a patient with contagious TB) and results of one of the
IGRA tested (QuantiFERON Gold In tube test: QFT) was
highly significant. This was not the case, however, for the
T-SPOT.TB or the TST. In this study, QFT was twice as ef-
fective at detecting probable LTBI (46%, Table 1) as either
the T-SPOT.TB (22%) or TST (25%). Even after adjustment
for age, and previous BCG vaccination, haemodialysis pa-
tients with probable LTBI had an OR of 4.6 of having a
positive QFT (Table 2). Conversely, OR for detecting latent
tuberculosis for either T-SPOT.TB or TST was not signifi-
cant. Furthermore, detection of patients with prior TB was
very low: among five patients with prior TB, T-SPOT.TB
and TST identified only one, while QFT identified two. As
previously reported, the best predictor of a positive TST was
prior BCG vaccination. QFT (8%) and T-SPOT.TB (11%)
had similar rates of indeterminate tests.
IGRAs have been studied in various groups of immuno-
compromised subjects (HIV infection, immuno-suppressed
haematology patients, auto-immune diseases, silicosis, can-
cer) [11,12,16]. Although responses to IGRA are slightly
reduced in immuno-suppressed subjects, when compared
with immuno-competent individuals, positivity rate of
IGRA is substantially higher than that of TST [11]. Two
studies specifically included patients with chronic renal
failure. Kobashi et al. [12] performed simultaneously TST
and QFT in 252 immuno-compromised patients among
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which 50 had chronic renal failure. Indeterminate rate was
4% for QFT in these 50 subjects (versus 12.7% for all
patients included). The rate of indeterminate tests was as-
sociated with immunosuppressive treatments, but not with
underlying disease. The sensitivity of QFT in this specific
group is not reported. Passalent et al. [13] studied 203
patients with end-stage renal disease and dialysis: in this
report, a positive T-SPOT.TB was strongly associated with
age, history of TB, high incidence of TB in country of
birth and radiological markers of TB, which was not the
case for TST. Conversely, as in our study, a positive TST
was associated with BCG vaccination. Among patients with
self-reported history of TB, sensitivity of T-SPOT.TB was
78.6% versus 21.4% for the TST, i.e. 4-fold higher. Based
on these findings, the authors advocate a combination of
T-SPOT.TB and medical assessment to diagnose latent tu-
berculosis instead of relying on the TST [13]. The rate of
indeterminate T-SPOT.TB results was 7%.
Our results confirm the higher predictive value of the
QFT for detecting LTBI versus TST (Tables 1–3). However,
the sensitivity of the T-SPOT.TB was lower in this particu-
lar subset of patients (22%, Table 1) and similar to that of
TST (25%). This result was surprising, since sensitivity of
the T-SPOT.TB is usually reported as at least equivalent to
that of the QFT [11]. As mentioned, all blood samples were
transported within 3 h to our laboratory, which has several
years of experience in IGRA processing. The rate of inde-
terminate results is also slightly higher for both IGRA than
previously reported in chronic renal failure, although sim-
ilar to that encountered in malignant disease [12]. Among
possible explanations are low lymphocyte counts (n = 4),
and age above 75 years (n = 7) that have been shown to
increase indeterminate IGRA results [17].
Our study has a few limitations that should be mentioned.
First, the presumptive diagnosis of latent TB infection in
our study was based on a composite of history of expo-
sure and radiological features, and as such is not a true
gold standard. This is an inevitable limitation of diagnostic
tests for LTBI, since there is no gold standard for LTBI.
The definition of LTBI is therefore probabilistic, based ei-
ther on scores of exposures and/or contagiousness of index
case in the case of recent exposure, or on epidemiological
items clearly related to risk of LTBI such as age, incidence
of TB in country of origin and history of contact with a
case of active TB. Relying on chest X-rays suggestive of
prior TB only would require a substantially larger group of
subjects.
Secondly, no booster testing was performed for TST.
Indeed, a significant increase in the rate of positive TST
after one or two booster injections has been reported [18–
21]. However, the problem of the low specificity of the TST
is not improved by booster injections: correlation of TST
with chest X-ray images suggestive of prior TB or history of
prior TB, when reported, is either weak or non-significant
[20, 21]. Because it is time consuming, subject to variability
between different readers, and does not improve specificity,
we did not perform booster injections and chose to compare
IGRA with a unique TST, which is the current procedure in
our institution.
Finally, samples sizes limit the reliability of any direct
comparison of performances of both IGRAs.
In summary, our results confirm the poor diagnostic
value of TST testing in haemodialysis patients and question
the use of TST alone for screening for latent tuberculosis
infection. The best predictor of a positive TST was prior
BCG, which illustrates the limited specificity of the TST.
Although one of the IGRAs tested (QFT) showed a 2-fold
increase in sensitivity for detecting LTBI, when compared
to TST, results of the T-SPOT.TB were not significantly
related to a presumptive diagnosis of LTBI. As expected,
agreement between IGRA and TST was low; more surpris-
ingly, agreement between IGRAs was only fair. Detection
of patients with prior TB was very low with TST and both
IGRA. The rate of indeterminate tests was rather high for
both tests. These results suggest that, in our population,
the QFT was superior to TST for detecting LTBI, but both
IGRAs and TST have important limitations. Based on our
results, we would recommend that detection of latent tuber-
culosis in haemodialysis patients be based on a combination
of an IGRA and a thorough evaluation of risk factors, and
radiological assessment. Whether QFT is clearly superior
to T-SPOT.TB in this population should be confirmed by
further studies.
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Abstract
Background. Anemia management remains complicated
in patients with endstage renal disease on hemodialysis.
We wished to evaluate the effect of protocol adherence to
EPO and intravenous iron dosing on achieving the desired
range of hemoglobin levels.
Methods. A cohort of hemodialysis patients was studied
to evaluate the rate of adherence to EPO and iron dosing
protocols over a 5 month period. A database was completed
to evaluate all known comorbidities, demographic factors,
and facility issues that might affect hemoglobin levels. A
logistic regression model was employed to evaluate the ef-
fect of adherence to the anemia protocols on the probability
of achieving a hemoglobin level below, within or above the
targeted range of 11–12.5g/dl.
Results. Among 2114 patients, we found that adherence to
both the EPO and iron dosing protocol resulted in the great-
est probability of achieving the target hemoglobin range
(56 ± 5% in anemia protocol adherent patients versus
42 ± 7% in non adherent patients). This was predominantly
due to a lowered risk of having above target hemoglobin
levels rather than below. The use of the anemia protocols
was associated with lower rates of hospitalization (9 ± 0.7
visits/100 months in adherent group vs 15 ± 2 in non ad-
herent group) and lower utilization of both EPO and intra-
venous iron. Furthermore, patients in the adherent groups
had less variability of their hemoglobin levels month by
month, at least as judged by standard deviation.
Conclusion. Adherence to anemia protocols, as practiced
in the dialysis units included in this cohort, may improve
hemodialysis patients’ ability to achieve target hemoglobin
levels, and by avoiding above target hemoglobin values,
lower drug utilization and reduce variability of hemoglobin
levels.
Keywords: anaemia management; ESRD; processes of care
C© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please e-mail: journals.permissions@oxfordjournals.org
